



ST-001 (nanoFENRETINIDE IV): Repurposed Retinoid Treatment for COVID-19 ARDS

FENRETINIDE, the active ingredient in ST-001:



ST-001 (nanoFENRETINIDE IV) Resumé

- Repurposing ST-001 from oncology to COVID-19
- Cross-filing on SciTech's current oncology IND #135475 to expedite clinical entry
- Utilize ST-001 manufacturing process from IND #135475
- ST-001 is SciTech's patented (expires 2030) formulation to administer high strength fenretinide via 4 hr infusion
- Only triglyceride-free IV formulation of fenretinide, avoiding other product's hypertriglyceridemia toxicity
- Phase 1 starting dose level targets a blood level above the IC₅₀ of 2 μM for SARS-CoV-2
- 20 μM blood levels of fenretinide have demonstrated safety in prior trials of other formulations
- Fenretinide is a safer analog of Vitamin A
- Compatible with monoclonal antibody therapies in published preclinical studies

CLINICAL DEVELOPMENT OF ST-001

IND Filed/ST-001 Manufacturing	Phase 1a	Phase 1b	Phase 2...
	Rapid Dose-Finding Design: <ul style="list-style-type: none"> • Establish Safety • Identify Treatment Dose • Proof of Concept <ul style="list-style-type: none"> - Reduced IL-6 - Increased IL-22BP • Explore Efficacy <ul style="list-style-type: none"> - Reduced D-dimer - Negative COVID-19 test 	Phase 1a Treatment Dose: <ul style="list-style-type: none"> • Confirm Safety • Explore Efficacy <ul style="list-style-type: none"> - Respiratory status - Reduced mortality - Reduced ICU LOS - Improved lab values • Confirm POC <ul style="list-style-type: none"> - IL-6 - IL-22BP 	Treatment Dose: <ul style="list-style-type: none"> • Efficacy/outcome endpoints after FDA consultation
↓			
	Phase 1		Phase 2...
ST-001 COMBINATION THERAPIES:	ST-001 Treatment Dose with Remdesivir, Kineret, Sylvant, or Actemra: <ul style="list-style-type: none"> • Confirm Safety • Explore Efficacy • Select best combination 		ST-001 Combination Treatment: <ul style="list-style-type: none"> • Efficacy/outcome endpoints after FDA consultation